Traders purchased shares of Pfizer Inc. (NYSE:PFE) on weakness during trading on Wednesday. $201.32 million flowed into the stock on the tick-up and $92.94 million flowed out of the stock on the tick-down, for a money net flow of $108.38 million into the stock. Of all equities tracked, Pfizer had the 9th highest net in-flow for the day. Pfizer traded down ($0.08) for the day and closed at $34.80

Several research firms have recently weighed in on PFE. Societe Generale set a $34.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Wednesday, May 4th. Independent Research GmbH set a $37.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Wednesday, May 4th. BMO Capital Markets reaffirmed a “buy” rating and issued a $40.00 price target (up previously from $39.00) on shares of Pfizer in a report on Wednesday, May 4th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a report on Friday, May 6th. Finally, Credit Suisse Group AG upped their price target on shares of Pfizer from $38.00 to $39.00 and gave the stock an “outperform” rating in a report on Monday, May 9th. Ten analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $38.82.

The firm’s 50-day moving average price is $35.74 and its 200 day moving average price is $33.43. The firm has a market capitalization of $211.08 billion and a price-to-earnings ratio of 30.85.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. The business earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. During the same quarter last year, the firm earned $0.56 earnings per share. The business’s quarterly revenue was up 10.9% on a year-over-year basis. On average, analysts expect that Pfizer Inc. will post $2.46 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 1st. Investors of record on Friday, August 5th will be paid a dividend of $0.30 per share. The ex-dividend date is Wednesday, August 3rd. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.45%.

Several institutional investors have recently added to or reduced their stakes in the company. SNS Financial Group LLC boosted its position in Pfizer by 9.1% in the fourth quarter. SNS Financial Group LLC now owns 62,206 shares of the biopharmaceutical company’s stock worth $2,008,000 after buying an additional 5,192 shares in the last quarter. CAM Group Holding A S boosted its position in Pfizer by 111.2% in the fourth quarter. CAM Group Holding A S now owns 1,148,915 shares of the biopharmaceutical company’s stock worth $37,087,000 after buying an additional 605,000 shares in the last quarter. Pettyjohn Wood & White Inc. boosted its position in Pfizer by 2.7% in the fourth quarter. Pettyjohn Wood & White Inc. now owns 83,918 shares of the biopharmaceutical company’s stock worth $2,709,000 after buying an additional 2,200 shares in the last quarter. Wellington Shields & Co. LLC boosted its position in Pfizer by 17.4% in the fourth quarter. Wellington Shields & Co. LLC now owns 52,579 shares of the biopharmaceutical company’s stock worth $1,697,000 after buying an additional 7,809 shares in the last quarter. Finally, Holderness Investments Co. boosted its position in Pfizer by 0.8% in the fourth quarter. Holderness Investments Co. now owns 65,817 shares of the biopharmaceutical company’s stock worth $2,125,000 after buying an additional 550 shares in the last quarter.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.